Amylyx Pharmaceuticals, Inc. (AMLX)

Current Report Filed: 2026-03-24

Key Insights

Amylyx Pharmaceuticals has completed enrollment in the Phase 3 LUCIDITY trial, a key milestone in the development of its lead drug candidate.
The company has added new exploratory analysis from the Phase 2 PREVENT study to its corporate presentation, potentially providing additional insights into the product's efficacy.
Amylyx has also completed enrollment for Cohort 2 in the Phase 1 LUMINA trial, further advancing its pipeline.

Insider Trading Filed: 2026-03-09

Key Insights

The reporting person, Joshua B. Cohen, acquired 248,865 shares of common stock and was granted a stock option to purchase 373,295 shares, indicating insider ownership and commitment to the company.
The restricted stock units (RSUs) and stock options granted to the reporting person have vesting schedules over multiple years, aligning his interests with long-term shareholder value creation.
The reporting person's role as Co-Chief Executive Officer suggests he has a significant influence on the company's strategic direction and decision-making.

Insider Trading Filed: 2026-03-09

Key Insights

The reporting person, Gina Mazzariello, who is the Chief Legal Officer of Amylyx Pharmaceuticals, Inc., has been granted 74,660 restricted stock units (RSUs) and 111,990 stock options as part of her compensation package.
The RSUs will vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to Mazzariello's continued service to the company.
The stock options will vest 25% on March 1, 2027, and the remaining shares will vest monthly over the next 36 months, also subject to Mazzariello's continuous service.

Insider Trading Filed: 2026-03-09

Key Insights

The reporting person, James M. Frates, is the Chief Financial Officer of Amylyx Pharmaceuticals, Inc. (AMLX) and has received a restricted stock unit (RSU) award of 95,990 shares, as well as a stock option to purchase 143,985 shares.
Frates also holds additional shares of AMLX stock indirectly through various trusts, indicating his significant ownership stake in the company.
The vesting schedule for the RSU award and stock option suggests a long-term incentive alignment between Frates and the company's performance.

Insider Trading Filed: 2026-03-09

Key Insights

The reporting person, Justin B. Klee, received a restricted stock unit (RSU) award of 248,865 shares and a stock option grant of 373,295 shares, indicating potential alignment between executive and shareholder interests.
The RSUs and stock options vest over multiple years, suggesting a long-term focus on the company's growth and performance.
The significant amount of shares acquired by the reporting person, who is also a Co-Chief Executive Officer, indicates a strong belief in the company's future prospects.

Insider Trading Filed: 2026-03-09

Key Insights

Camille L. Bedrosian, the Chief Medical Officer of Amylyx Pharmaceuticals, received a grant of 95,990 restricted stock units (RSUs) and a stock option to purchase 143,985 shares, signaling the company's commitment to retaining key leadership.
The RSUs will vest in 4 equal annual installments, with the first tranche vesting in March 2027, incentivizing Bedrosian to remain with the company long-term.
The stock option has a 10-year term, with 25% vesting immediately and the remaining shares vesting monthly over the next 3 years, aligning Bedrosian's interests with those of shareholders.

Insider Trading Filed: 2026-02-04

Key Insights

The reporting person, Gina Mazzariello, who is the Chief Legal Officer of Amylyx Pharmaceuticals, Inc., sold 3,448 shares of the company's common stock on February 2, 2026, likely to cover tax withholding obligations in connection with the vesting of restricted stock units.
The sale was executed at a weighted average price of $14.6507 per share, with the shares sold in multiple transactions at prices ranging from $14.470 to $14.810.
Following the reported transaction, the reporting person beneficially owns 144,693 shares of the company's common stock, indicating ongoing significant ownership stake in the company.

Insider Trading Filed: 2026-02-04

Key Insights

Chief Financial Officer James M. Frates sold 3,557 shares of Amylyx Pharmaceuticals, Inc. (AMLX) stock on February 2, 2026 at a weighted average price of $14.6463.
Frates holds an additional 100,000 shares indirectly through a trust and has indirect ownership of 15,459 and 11,072 shares through two other trusts.
The sale appears to be for tax withholding purposes related to the vesting of restricted stock units, rather than a discretionary sale.

Insider Trading Filed: 2026-02-04

Key Insights

The reporting person, Joshua B. Cohen, who is the Co-Chief Executive Officer of Amylyx Pharmaceuticals, Inc. (AMLX), sold 15,500 shares of the company's common stock on 02/02/2026.
The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units, and the sales were automatic and not at the discretion of the reporting person.
The reporting person continues to beneficially own 3,363,965 shares of the company's common stock, indicating that he maintains a significant ownership stake in the company.

Insider Trading Filed: 2026-02-04

Key Insights

The reporting person, Justin B. Klee, who is the Co-Chief Executive Officer of Amylyx Pharmaceuticals, Inc., sold 15,500 shares of the company's common stock on February 2, 2026 to cover tax withholding obligations related to the vesting of restricted stock units.
The shares were sold at a weighted average price of $14.685, indicating a total transaction value of approximately $227,600.
Following the transaction, the reporting person still holds 3,363,898 shares of the company's common stock, representing a significant ownership stake in the company.

Insider Trading Filed: 2026-01-20

Key Insights

The reporting person Joshua B. Cohen, who is the Co-Chief Executive Officer of Amylyx Pharmaceuticals, Inc. (AMLX), has exercised and sold a significant number of stock options, suggesting potential insider activity.
The reported transactions indicate that Cohen is selling a portion of his AMLX shares, potentially for personal reasons or to cover option costs and tax obligations.
The timing of these transactions, just a few months before the stock option expiration, may be worth further investigation to understand Cohen's motivations and the potential impact on the company's stock price.

Insider Trading Filed: 2026-01-20

Key Insights

The reporting person, Justin B. Klee, the Co-Chief Executive Officer of Amylyx Pharmaceuticals, exercised stock options and subsequently sold a portion of the shares to cover the option cost and tax obligations, indicating ongoing insider activity.
Klee's stock sales were made pursuant to a pre-established 10b5-1 trading plan, suggesting a systematic approach to managing his equity position.
The reported transactions occurred on January 15 and 16, 2026, with the exercise of options at a strike price of $7.57 and the subsequent sale of shares at weighted average prices of $13.58 and $13.89, respectively.

Insider Trading Filed: 2026-01-14

Key Insights

Insider George M. Milne Jr. gifted 17,780 shares of Amylyx Pharmaceuticals stock, reducing his direct ownership to 812,881 shares.
The timing and amount of the gift transaction suggest Milne may have confidence in the company's future prospects.
Insider transactions can provide insights into management's views, though the motivations behind this gift are unclear without additional context.

Current Report Filed: 2026-01-08

Key Insights

Amylyx Pharmaceuticals has selected a new development candidate, AMX0318, a long-acting GLP-1 receptor antagonist, for the treatment of post-bariatric hypoglycemia and other rare diseases.
The selection of AMX0318 triggers milestone payments of $4 million to Gubra, Amylyx's research partner, under the terms of their collaboration agreement.
Amylyx has updated its corporate presentation for investor meetings, providing insight into the company's pipeline and development plans.

Insider Trading Filed: 2026-01-08

Key Insights

The reporting person, James M. Frates, Chief Financial Officer of Amylyx Pharmaceuticals, Inc., sold 3,326 shares of the company's common stock on January 6, 2026 to cover tax withholding obligations in connection with the vesting of restricted stock units.
The reporting person holds additional indirect beneficial ownership of 100,000 shares through a grantor retained annuity trust, 15,459 shares through another trust, and 11,072 shares through the Frates Family 2013 Irrevocable Trust.
The reporting person's sale of shares appears to be a routine transaction to cover tax obligations and not an indication of a significant change in his overall ownership position.

Insider Trading Filed: 2026-01-08

Key Insights

The reporting person, Joshua B. Cohen, sold 7,715 shares of Amylyx Pharmaceuticals, Inc. (AMLX) common stock on January 6, 2026, which appears to be a sale to cover tax withholding obligations in connection with the vesting of restricted stock units.
Cohen, who is a Co-Chief Executive Officer and Director of the company, still beneficially owns 3,317,632 shares of AMLX common stock following the reported transaction.
The sale was executed at a weighted average price of $11.0948 per share, which appears to be within the normal trading range for the stock.

Insider Trading Filed: 2026-01-08

Key Insights

Insider Justin B. Klee, the Co-Chief Executive Officer, sold 7,715 shares of Amylyx Pharmaceuticals, Inc. (AMLX) on 01/06/2026 at an average price of $11.0939 per share. This sale represents a small fraction of his total ownership of over 3.3 million shares.
The sale appears to have been an automatic transaction to cover tax withholding obligations related to the vesting of restricted stock units, rather than a discretionary sale by the insider.
This insider transaction does not indicate a significant change in the insider's overall beneficial ownership position or a bearish sentiment towards the company.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information